Ascendis Pharma A/S (ASND) Stock Price, News & Analysis

Company Overview

Ascendis Pharma A/S is a biopharmaceutical company focused on the development and commercialization of innovative therapies for rare endocrine and growth disorders. Leveraging its proprietary TransCon™ drug delivery technology, the company designs long-acting prodrugs that aim to improve efficacy, safety and patient convenience. Ascendis operates from its global headquarters in Hellerup, Denmark, with significant research, development and commercial offices in the United States and partnerships across Europe and Asia.

The company’s lead product candidates address conditions such as pediatric growth hormone deficiency, hypoparathyroidism and achondroplasia. TransCon Growth Hormone is being evaluated as a once-weekly replacement therapy for children and adults with growth hormone deficiency. TransCon PTH, a prodrug of parathyroid hormone, is in clinical development for the treatment of chronic hypoparathyroidism, offering potential benefits over existing therapies through stable, physiologic hormone exposure. Additionally, TransCon CNP is designed to stimulate bone growth in children with achondroplasia, targeting the underlying cause of shortened stature.

Since its establishment, Ascendis Pharma has grown from a small research organization into a global biopharmaceutical company, bolstered by strategic collaborations with academic institutions and industry partners. Its manufacturing capabilities span both clinical and commercial scales, and the company has regulatory interactions with health authorities in multiple regions to support registration and launch efforts. Ascendis’ comprehensive pipeline also includes next-generation candidates for endocrine and metabolic diseases, underscoring its commitment to addressing unmet medical needs.

Leadership at Ascendis Pharma combines expertise in drug development, regulatory affairs and global commercialization. Under the direction of CEO Jan Mikkelsen and an experienced executive team, the company is advancing its late-stage programs toward potential regulatory approvals and preparing for broader market access. With a patient-centric approach and a robust technology platform, Ascendis aims to transform the treatment landscape for rare disorders worldwide.

Key Stats

• Today's Range: $173.78 to $177.18
• 50-Day Range: $151.25 to $179.10
• 52-Week Range: $111.09 to $183.00
• Volume: 387,284 shs
• Average Volume: 506,119 shs
• Market Capitalization: $10.70 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $223.07
• Consensus Rating: Buy

Ascendis Pharma A/S Stock Analysis - MarketRank™

Ascendis Pharma A/S scored higher than 72% of companies evaluated by MarketBeat, and ranked 293rd out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Ascendis Pharma A/S has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 15 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Ascendis Pharma A/S has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Ascendis Pharma A/S are expected to grow in the coming year, from ($4.34) to $0.24 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Ascendis Pharma A/S is -27.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Ascendis Pharma A/S is -27.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.16% of the float of Ascendis Pharma A/S has been sold short.

Short Interest Ratio / Days to Cover

Ascendis Pharma A/S has a short interest ratio ("days to cover") of 4.5.

Change versus previous month

Short interest in Ascendis Pharma A/S has recently decreased by 15.99%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ascendis Pharma A/S does not currently pay a dividend.

Dividend Growth

Ascendis Pharma A/S does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.16% of the float of Ascendis Pharma A/S has been sold short.

Short Interest Ratio / Days to Cover

Ascendis Pharma A/S has a short interest ratio ("days to cover") of 4.5.

Change versus previous month

Short interest in Ascendis Pharma A/S has recently decreased by 15.99%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.95

News Sentiment

Ascendis Pharma A/S has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Ascendis Pharma A/S this week, compared to 7 articles on an average week.

Search Interest

14 people have searched for ASND on MarketBeat in the last 30 days. This is an increase of 180% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Ascendis Pharma A/S insiders have not sold or bought any company stock.

Percentage Held by Insiders

40.00% of the stock of Ascendis Pharma A/S is held by insiders. A high percentage of insider ownership can be a sign of company health.

ASND Stock Analysis - Frequently Asked Questions

How have ASND shares performed this year?

Ascendis Pharma A/S's stock was trading at $137.67 at the beginning of 2025. Since then, ASND shares have increased by 27.1% and is now trading at $174.96.

How were Ascendis Pharma A/S's earnings last quarter?

Ascendis Pharma A/S (NASDAQ:ASND) announced its quarterly earnings results on Thursday, May, 1st. The biotechnology company reported ($1.66) earnings per share for the quarter, missing the consensus estimate of ($1.56) by $0.10. The biotechnology company had revenue of $123.97 million for the quarter, compared to the consensus estimate of $98.56 million.
Read the conference call transcript.

When did Ascendis Pharma A/S IPO?

Ascendis Pharma A/S (ASND) raised $85 million in an initial public offering (IPO) on Wednesday, January 28th 2015. The company issued 5,000,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and Wells Fargo Securities was co-manager.

Who are Ascendis Pharma A/S's major shareholders?

Ascendis Pharma A/S's top institutional shareholders include Harbor Capital Advisors Inc. (0.13%) and Diversified Trust Co (0.07%).

How do I buy shares of Ascendis Pharma A/S?

Shares of ASND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Ascendis Pharma A/S own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ascendis Pharma A/S investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), Novo Nordisk A/S (NVO) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 5/01/2025
• Today: 7/13/2025
• Next Earnings (Estimated): 9/02/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ASND
• CIK: 1612042
• Web: www.ascendispharma.com
• Phone: (457) 022-2244
• Fax: 45-3694-4010
• Employees: 1,017
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Ascendis Pharma A/S: $223.07
• High Price Target: $289.00
• Low Price Target: $153.00
• Potential Upside/Downside: +27.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): ($6.28)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$409.12 million
• Net Margins: -93.22%
• Pretax Margin: -92.10%
• Return on Equity: N/A
• Return on Assets: -33.29%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.04
• Quick Ratio: 0.71

Sales & Book Value

• Annual Sales: $393.54 million
• Price / Sales: 27.18
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.88) per share
• Price / Book: -93.06

Miscellaneous

• Outstanding Shares: 61,130,000
• Free Float: 36,679,000
• Market Cap: $10.70 billion
• Optionable: Optionable
• Beta: 0.38